AUSTIN, Texas, Dec. 10, 2019 /PRNewswire/ -- Spindletop
Capital Management, a healthcare-focused growth equity firm, is
pleased to announce the promotion of Kelly Huang, Ph.D.
as a Managing Director of Spindletop Capital. The
promotion was in recognition of Dr. Huang's role in
identifying successful growth equity investments and working
closely with portfolio companies' management teams to accelerate
revenue and profit growth. Dr. Huang
first joined Spindletop Capital in 2014 as an advisor
and operating partner.
Dr. Huang is an integrator of science, business, and customer
needs in healthcare and comes with deep experience in leading
growth and innovative sales and marketing programs with
physicians. Recently, he served as President, CEO, &
Board Director for Obalon Therapeutics (NASDAQ: OBLN). From
April 2015 to September 2017, Dr. Huang was the General Manager
of Nestle Skin Health's Galderma LP Aesthetics business providing
commercial leadership for Iconic brands like Restylane, Dysport,
and Sculptra. From Aug 2011 to
Feb 2014, Dr. Huang was with Endo
Pharmaceuticals as the President of HealthTronics and a member of
Endo's Executive Committee, responsible for strategic leadership
across the Branded & Generic Pharmaceuticals, Medical Devices,
and Medical Services sectors. Before Endo, he was with
Johnson & Johnson for 16 years, including Neutrogena as the
Vice President of Research and Development from August 2009 to August
2011; Vice President with Johnson & Johnson's
Development Corporation from January
2006 to July 2009.
"We congratulate Kelly with his new role on our team at
Spindletop," notes Dr. Evan Melrose, Managing Director at
Spindletop Capital. "Kelly has been a tremendous asset to the
Spindletop organization as an advisor, operating partner, and
member of our investment committee for the last two funds.
The combination of his operating experience, investment track
record, and technical acumen complements our team and our
portfolio CEO's as they experience rapid growth."
ABOUT SPINDLETOP CAPITAL MANAGEMENT
Spindletop
Capital, founded in 2011, is a healthcare investment firm focused
on providing expansion capital for commercial-stage healthcare
companies. Based in Austin, Spindletop is managed by an
unrivaled team of investment professionals and advisors with deep
operating, technical, and transactional experience. Spindletop
Capital leverages the organization's deep experience, broad
network, and proprietary access to Texas resources to
enhance value for management teams and financing syndicates.
Spindletop Capital invests nationally across all sectors of
healthcare, including medical devices, diagnostics, healthcare
services, healthcare IT, specialty pharmaceuticals and
biotechnology.
For more information, visit www.spindletopcapital.com
Media Contact: Christina Weathersbee Spindletop Capital
512‐961‐4633 admin[AT]Spindletopcapital.com
View original
content:http://www.prnewswire.com/news-releases/spindletop-capital-management-promotes-kelly-huang-phd-to-managing-director-300972542.html
SOURCE Spindletop Capital Management